Novitskaia Ia G, Gribakina O G, Kolyvanov G B, Zherdev V P, Smirnov V V, Seredenin S B
Eksp Klin Farmakol. 2013;76(11):36-9.
The effect of subchronic peroral administration in effective doses of afobazole (5 mg/kg), and cytochrome P450 inductors (rifampicin, 13.4 mg/kg; phenytoin, 10.4 mg/kg) and inhibitors (fluconazole, 35.7 mg/kg; ciprofloxacin, 44.0 mg/kg) on the metabolic ratio (MR) of drugs-markers of CYP2C9 and CYP1A2 activity was studied in rats. Afobazole did not change the MR of compounds metabolized by the P450 isoforms studied. After peroral administration of standard P450 inductors and inhibitors, statistically significant bidirectional effects were identified, which demonstrated the expedience of administering a complex of selected compounds, markers, and CYP2C9 and CYP1A2 activity modificators for comparative evaluation of the effects of new drugs in rats. It is recommended to evaluate the activity of CYP1A2 by determining the MR for one of two caffeine metabolites, paraxanthine or theobromine, and the activity of CYP2C9 by determining the MR of metabolite Exp-3174 to losartan.
研究了阿伏唑(5毫克/千克)、细胞色素P450诱导剂(利福平,13.4毫克/千克;苯妥英,10.4毫克/千克)和抑制剂(氟康唑,35.7毫克/千克;环丙沙星,44.0毫克/千克)以有效剂量经口亚慢性给药对大鼠体内CYP2C9和CYP1A2活性的药物标志物代谢比(MR)的影响。阿伏唑未改变所研究的P450同工酶代谢的化合物的MR。经口给予标准P450诱导剂和抑制剂后,确定了具有统计学意义的双向效应,这表明给予选定化合物、标志物以及CYP2C9和CYP1A2活性调节剂复合物用于比较评估大鼠新药效应是可行的。建议通过测定两种咖啡因代谢物之一(副黄嘌呤或可可碱)的MR来评估CYP1A2的活性,并通过测定代谢物Exp-3174与氯沙坦的MR来评估CYP2C9的活性。